Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma
Open Access
- 24 January 2022
- journal article
- research article
- Published by Taylor & Francis in Hematology
- Vol. 27 (1) , 105-112
Abstract
The prognosis of patients with relapsed and refractory primary central nervous system diffuse large B cell lymphoma (PCNSL) is poor and there is no standard salvage treatment currently available. Gene expression profiling and next-generation sequencing have provided massive amounts of data, revealing the pathogenic mechanism of PCNSL and identifying potential mechanisms for therapeutic exploration. Here, we review targeted drugs that may change the current treatment model of PCNSL.Keywords
Funding Information
- Nantong science and technology project (HS2019003)
This publication has 37 references indexed in Scilit:
- Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS LymphomaJournal of Clinical Oncology, 2016
- Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin LymphomaJournal of Clinical Oncology, 2015
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaNature Medicine, 2015
- Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphomaNeurology, 2015
- Methotrexate re-challenge for recurrent primary central nervous system lymphomaJournal of Neuro-Oncology, 2014
- Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine ModelsPLOS ONE, 2013
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphomaAnnals of Oncology, 2011
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2008
- Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant GliomaClinical Cancer Research, 2007
- Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progressionOncogene, 2004